Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

SML1991

Sigma-Aldrich

PS432

≥98% (HPLC)

Synonym(s):

2-[5-(4-chlorophenyl)-2-furanyl]-2,5-dihydro-4-hydroxy-1-(6-methyl-2-benzothiazolyl)-5-oxo-1H-pyrrole-3-carboxylic acid ethyl ester

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
¥11,390

¥11,390

Estimated to ship onMay 30, 2025

New, lower price on this item!
Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
¥11,390

About This Item

Empirical Formula (Hill Notation):
C25H19ClN2O5S
CAS Number:
2083630-26-4
Molecular Weight:
494.95
UNSPSC Code:
12352200
NACRES:
NA.77

¥11,390

Estimated to ship onMay 30, 2025

New, lower price on this item!
Request a Bulk Order

Assay

≥98% (HPLC)

color

white to beige

solubility

DMSO: 2 mg/mL, clear

shipped in

ambient

storage temp.

2-8°C

SMILES string

O=C1C(O)=C(C(OCC)=O)C(C2=CC=C(C3=CC=C(Cl)C=C3)O2)N1C4=NC(C=CC(C)=C5)=C5S4

Biochem/physiol Actions

Allosteric inhibitor of atypical PKC isoforms
PS432 is an allosteric inhibitor of Protein Kinase C (PKC) that targets regulatory site (PIF-pocket) present in the kinase domain. PS432 potently inhibits non-small cell lung cancer cells proliferation and tumor growth without side effects in a mouse xenograft model.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

SML1991-25MG:
SML1991-VAR:
SML1991-5MG:
SML1991-BULK:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jose M Arencibia et al.
ACS chemical biology, 12(2), 564-573 (2017-01-04)
There is a current and pressing need for improved cancer therapies. The use of small molecule kinase inhibitors and their application in combinatorial regimens represent an approach to personalized targeted cancer therapy. A number of AGC kinases, including atypical Protein

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service